This week in our colorectal cancer mini-series we have covered the validation of Immunoscore as a tool for determining which patients have high T cells in their tuours and are therefore candidates for single agent immunotherapy (Link), as well as microsatellite instability (MSI) and mismatch-repair deficient tumours and how they can respond immunotherapy (Link).
What happens in the majority (95%) of patients, the microsatellite stable (MSS) disease who are mismatch-repair proficient though? They don’t respond well to checkpoint blockade so how can we help them?
In Chicago, BSB interviewed Dr Johanna Bendell from the Sarah Cannon Research Institute in Nashville, Tennessee to find out more about what she and her colleagues have been doing and where they plan to go next.
You can learn about her perspectives from ASCO by logging in below or if you’re new then you can sign up for a BSB subscription via the blue box…
Chicago – it’s “Plenary Sunday” at the 2016 annual meeting of the American Society for Clinical Oncology (ASCO).
Cancer immunotherapy has arrived at ASCO! Not so long ago cancer immunotherapy presentations were in small meeting rooms and had only a few attendees – at this meeting cancer immunotherapy data is being presented to thousands of attendees in large meetings rooms, including the B1 plenary hall. What a difference in the space of a few years!
Today at ASCO there are several noteworthy cancer immunotherapy presentations. We’ll be writing about them here on the blog during the day.
Part of the opportunity of coming to a meeting such as ASCO is the networking opportunities it affords.
While in Chicago I heard about a phase 3 trial from a global pharma company that failed to meet its primary endpoint last year, however, – to the best of my knowledge – there’s been no publication or presentation of the negative data that may help the field move forward. The investigators have been told “it’s a bust.”
Not to publish or present negative data is a disservice to the patients that enrolled on the trial. Many would have believed their participation would contribute to the advancement of science and medicine, and potentially benefit others.
Want to know what the trial is and the company involved? Subscribers can login to find more or you can purchase access below to read more, along with our coverage of Sunday at ASCO 2016.
Update 12.30pm. Occasionally we decide something we talk about needs to be “open access” so we’ve published a short post. It is freely available to all. Turns out the negative data from BMS was mentioned in a July 23, 2015 financial results press release. Almost a year later, the negative data has still not been presented or published.